Anzeige
Mehr »
Login
Donnerstag, 25.04.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Wie die Revolution der sauberen Energie eine solide Investitionsmöglichkeit bieten könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
44 Leser
Artikel bewerten:
(0)

Roche, Teva, Eagle Genomics, Pfizer and Quest Diagnostics Look to Capitalize in the Global Precision Medicine Market

HYDERABAD, India, September 30, 2016 /PRNewswire/ --

Mordor Intelligence announces the publication of their research report on the precision medicine market. The report titled, "Global Precision Medicine Market - Growth, Trends & Forecasts (2016-2021)" discusses the current landscape and outlook of the said market.

The global precision medicine market is estimated to be USD 40 billion in 2016 and is expected to reach USD 65.3 billion by 2021, growing at a CAGR of 10.3% during the forecast period. The report is an amalgamation of the current market scenario, its prospects and forces driving and restraining the market growth. The report highlights the North American, European, Asia-Pacific, Latin American and Middle East & African markets.

Oncology is at the frontline of precision medicine, moving beyond the previous model of giving cancer therapeutics based on trials of largely unselected patients beyond a simple phenotypic marker, to leading the way in utilizing the molecular profile of an individual's cancer genome to optimize their disease management

Browse Related Reports Here

The market for precision medicine can be segmented based on technology (big data analytics, bioinformatics, gene sequencing, drug discovery, companion diagnostics and others), by application (Oncology, CNS, Immunology, Respiratory and Others), and by geography (North America, Europe, Asia-Pacific, Latin America and Middle East & Africa).

Precision medicine, a combination of molecular biology techniques and systems biology, is an emerging approach for disease treatment and prevention. The market growth for this approach is gaining momentum, as it takes into account individual variability in genes, environment, and lifestyle for each person while developing drugs and vaccines. Precision Medicine finds its majority of applications in Oncology diagnosis and therapeutics. Patients diagnosed with cancer in 2004 would have had only a 10.0% chance of obtaining the right treatment for the disease as compared to a 70.0-80.0% chance of getting the right treatment today.

The leading companies that dominate the precision medicine market are Biocrates Life Sciences, Nanostring Technologies, Tepnel Pharma Services, Intomics, Ferrer InCode, Covance, Silicon Biosystems (now part of the Menarini Group), Pfizer, Eagle Genomics, Source Precision Medicine, Laboratory Corporation of America Holdings, Medtronic Novartis, Qiagen, Quest Diagnostics, Roche Holding, Teva Pharmaceuticals, and others.

About Mordor Intelligence:

Mordor Intelligence is a global market research and consulting firm. Our focus is to provide research insights to facilitate business success. Our research expertise covers niche segments under Agriculture, Healthcare, ICT, Chemicals, Manufacturing, Logistics, Electronics and Automotive, among others. We believe in data, and we provide solutions through it. Optimum solutions and goal-oriented strategies define our endeavors and make us the preferred choice for clients.

For information regarding permissions and sales, please contact: info@mordorintelligence.com

Media Contact:
Madan Gopal
AVP - Marketing & Strategy
Email: madan@mordorintelligence.com
Direct Line: +1-617-765-2493

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2016 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.